Cargando…
TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
OBJECTIVE: Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the influence of thyroid hormones, TSH, TSH...
Autores principales: | Siderova, Mira, Hristozov, Kiril, Tsukeva, Aleksandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118993/ https://www.ncbi.nlm.nih.gov/pubmed/29768627 http://dx.doi.org/10.20945/2359-3997000000027 |
Ejemplares similares
-
Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2013) -
Comparison Between Thyroid Stimulating Immunoglobulin and
TSH-Receptor Antibodies in the Management of Graves’
Orbitopathy
por: Khamisi, Selwan, et al.
Publicado: (2023) -
Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays
por: Bluszcz, Gabriela A., et al.
Publicado: (2018) -
Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015) -
Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)